BMS-986446 in Healthy Adults and Early Alzheimer's Disease

Phase 1, open-label trial of nivolumab (subcutaneous) in Alzheimer's disease (AD) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous…, Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion and 10 more. Started Aug 2026; status: recruiting.